Immunological Landscape of HER-2 Positive Breast Cancer
Santiago Moragón, Cristina Hernándo, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Aňa Lluch, Begoña Bermejo, Juan Miguel Cejalvo
Abstract
Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.